Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Altimmune (NASDAQ:ALT) issued its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01, Zacks reports. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million.

Altimmune Trading Up 0.4 %

ALT traded up $0.03 on Friday, hitting $6.45. 556,250 shares of the company’s stock were exchanged, compared to its average volume of 2,159,669. The stock has a fifty day moving average of $6.88 and a two-hundred day moving average of $7.18. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.05. The firm has a market cap of $458.37 million, a PE ratio of -4.16 and a beta of 0.19.

Analysts Set New Price Targets

ALT has been the topic of a number of recent analyst reports. William Blair initiated coverage on Altimmune in a research report on Friday. They issued a “market perform” rating on the stock. UBS Group started coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Stifel Nicolaus began coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Altimmune has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.